ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the “FTC”) staff in connection with its Request for Additional Information and Documentary Material (the “Seco ...

Core Insights - LENSAR, Inc. reported a total revenue of $14.3 million for Q3 2025, marking a 6% increase from $13.5 million in Q3 2024, primarily driven by an 11% increase in worldwide procedure volume [3][4] - The installed base of ALLY Robotic Cataract Laser Systems grew by 77% year-over-year, with 185 systems installed as of September 30, 2025 [3][4] - The company is in the process of being acquired by Alcon, with expectations for the transaction to close in Q1 2026 [2][3] Financial Performance - Total revenue for Q3 2025 was $14.3 million, up from $13.5 million in Q3 2024, driven by increased procedure volume [3][4] - Recurring revenue accounted for 75% of total revenue in Q3 2025, compared to 73% in Q3 2024 [4] - The net loss for Q3 2025 was $3.7 million, or ($0.31) per share, compared to a net loss of $1.5 million, or ($0.13) per share, in Q3 2024 [6][18] Operational Highlights - The company placed 18 ALLY Systems in Q3 2025, contributing to a total installed base of approximately 425 laser systems, a 20% increase from the previous year [3][4] - Selling, general, and administrative expenses rose to $12.0 million in Q3 2025, up from $6.1 million in Q3 2024, largely due to acquisition-related costs [5][18] - Research and development expenses increased by 14% to $1.4 million in Q3 2025 compared to $1.2 million in Q3 2024 [5][18] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $16.9 million, down from $22.5 million at the end of 2024 [8][20] - The cash balance decreased by approximately $3.4 million during Q3 2025 [8]

Core Insights - LENSAR, Inc. reported strong operational performance in Q2 2025, with 18 ALLY Robotic Cataract Laser Systems installed and an additional 18 in backlog, reflecting a 107% growth in the installed base compared to Q2 2024 [1][2] - The company experienced a 23% increase in worldwide procedure volumes compared to the same quarter in the previous year [1][2] - The proposed merger with Alcon has received overwhelming support from shareholders, with over 99% of votes cast in favor, and is expected to close by the end of 2025 [2] Financial Performance - Total revenue for Q2 2025 was $13.9 million, a 10% increase from $12.6 million in Q2 2024, primarily driven by increased procedure volume [3][4] - Recurring revenue accounted for 82% of total revenue in Q2 2025, up from 79% in Q2 2024, with procedure revenue increasing to $8.3 million from $6.9 million year-over-year [4][5] - The net loss for Q2 2025 was $1.8 million, or ($0.15) per share, significantly reduced from a net loss of $9.0 million, or ($0.79) per share, in Q2 2024 [7][20] Operational Highlights - The installed base of ALLY Systems reached approximately 165 units, with a total combined installed base of LENSAR Laser Systems and ALLY Systems increasing to about 410, reflecting a 23% increase year-over-year [3][4] - Selling, general, and administrative expenses rose to $11.7 million in Q2 2025, a 72% increase from $6.8 million in Q2 2024, largely due to acquisition-related costs associated with the merger with Alcon [5][6] - Research and development expenses increased slightly to $1.4 million in Q2 2025 from $1.3 million in Q2 2024 [6] Market Position - LENSAR's laser systems accounted for over 21% of total U.S. cataract procedures in Q2 2025, marking a 3% increase from the previous year [3] - The company continues to focus on advanced robotic laser solutions for cataract treatment, positioning itself as a leader in the medical technology sector [11]

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, ...